PRLD insider transaction filings
Prelude Therapeutics Inc — 36 most recent Form 4 filings from SEC EDGAR, normalized by FilingPulse. Latest filing: 2026-06-10. Screen PRLD transaction legs live →
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-06-10 | 4 | Sandor Victor — Director | Grant/award (A): 38,000 (derivative) @ $0 | EDGAR |
| 2026-06-10 | 4 | Dorton Katina — Director | Grant/award (A): 38,000 (derivative) @ $0 | EDGAR |
| 2026-06-10 | 4 | Bonita David P — Director, 10% owner | Grant/award (A): 38,000 (derivative) @ $0 | EDGAR |
| 2026-06-10 | 4 | Babler Martin — Director | Grant/award (A): 38,000 (derivative) @ $0 | EDGAR |
| 2026-06-10 | 4 | FRIEDMAN PAUL A — Director | Grant/award (A): 38,000 (derivative) @ $0 | EDGAR |
| 2026-06-10 | 4 | BAKER BROS. ADVISORS LP — Director, 10% owner 667, L.P. — Director, 10% owner Baker Bros. Advisors (GP) LLC — Director, 10% owner Baker Brothers Life Sciences LP — Director, 10% owner BAKER FELIX — Director, 10% owner BAKER JULIAN — Director, 10% owner | Grant/award (A): 38,000 (derivative) @ $0 · Grant/award (A): 38,000 (derivative) @ $0 | EDGAR |
| 2026-05-04 | 4 | Morris Charles Q — Chief Medical Officer | Grant/award (A): 450,000 (derivative) @ $4.70 | EDGAR |
| 2026-04-28 | 4 | RA CAPITAL MANAGEMENT, L.P. — 10% owner RA Capital Healthcare Fund LP — 10% owner Kolchinsky Peter — 10% owner Shah Rajeev M. — 10% owner | Other (J): 1,407,000 · Other (J): 1,407,000 (derivative) | EDGAR |
| 2026-04-23 | 4 | Bonita David P — Director, 10% owner | Purchase (P): 1,689,189 @ $4.44 · Purchase (P): 1,126,126 @ $4.44 | EDGAR |
| 2026-04-23 | 4 | ORBIMED ADVISORS LLC — Director, 10% owner OrbiMed Capital GP VI LLC — Director, 10% owner ORBIMED CAPITAL LLC — Director, 10% owner OrbiMed Genesis GP LLC — Director, 10% owner | Purchase (P): 1,689,189 @ $4.44 · Purchase (P): 1,126,126 @ $4.44 | EDGAR |
| 2026-04-22 | 4 | BAKER BROS. ADVISORS LP — Director, 10% owner 667, L.P. — Director, 10% owner Baker Bros. Advisors (GP) LLC — Director, 10% owner Baker Brothers Life Sciences LP — Director, 10% owner BAKER FELIX — Director, 10% owner BAKER JULIAN — Director, 10% owner | Purchase (P): 114,601 (derivative) @ $4.44 · Purchase (P): 2,137,651 (derivative) @ $4.44 | EDGAR |
| 2026-02-05 | 4 | Combs Andrew — Chief Chemistry Officer | Grant/award (A): 230,000 (derivative) @ $0 | EDGAR |
| 2026-02-05 | 4 | Vaddi Krishna — CEO, Director | Grant/award (A): 837,000 (derivative) @ $0 | EDGAR |
| 2026-02-05 | 4 | Scherle Peggy — Chief Scientific Officer | Grant/award (A): 230,000 (derivative) @ $0 | EDGAR |
| 2026-02-05 | 4 | Lim Bryant David — CLO, CFO, Corp Sec. | Grant/award (A): 275,000 (derivative) @ $0 | EDGAR |
| 2025-11-07 | 4 | Sandor Victor — Director | Grant/award (A): 121,285 (derivative) @ $0 | EDGAR |
| 2025-10-20 | 4 | Dorton Katina — Director | Grant/award (A): 76,000 (derivative) @ $0 | EDGAR |
| 2025-10-07 | 4 | Huang Jane — President, CMO | Option exercise (M): 9,375 · Tax withholding (F): 3,355 @ $1.47 · Option exercise (M): 9,375 (derivative) @ $0 | EDGAR |
| 2025-07-08 | 4 | Huang Jane — President, CMO | Option exercise (M): 9,375 · Tax withholding (F): 3,355 @ $0.79 · Option exercise (M): 9,375 (derivative) @ $0 | EDGAR |
| 2025-06-13 | 4 | Sandor Victor — Director | Grant/award (A): 38,000 (derivative) @ $0 | EDGAR |
| 2025-06-13 | 4 | Dier Mardi — Director | Grant/award (A): 38,000 (derivative) @ $0 | EDGAR |
| 2025-06-13 | 4 | Bonita David P — Director, 10% owner | Grant/award (A): 38,000 (derivative) @ $0 | EDGAR |
| 2025-06-13 | 4 | Babler Martin — Director | Grant/award (A): 38,000 (derivative) @ $0 | EDGAR |
| 2025-06-13 | 4 | FRIEDMAN PAUL A — Director | Grant/award (A): 38,000 (derivative) @ $0 | EDGAR |
| 2025-06-13 | 4 | BAKER BROS. ADVISORS LP — Director, 10% owner 667, L.P. — Director, 10% owner Baker Bros. Advisors (GP) LLC — Director, 10% owner Baker Brothers Life Sciences LP — Director, 10% owner BAKER FELIX — Director, 10% owner BAKER JULIAN — Director, 10% owner | Grant/award (A): 76,000 (derivative) @ $0 · Grant/award (A): 76,000 (derivative) @ $0 | EDGAR |
| 2025-04-07 | 4 | Huang Jane — President, CMO | Option exercise (M): 9,375 · Tax withholding (F): 3,355 @ $0.68 · Option exercise (M): 9,375 (derivative) @ $0 | EDGAR |
| 2025-03-27 | 4 | Combs Andrew — Chief Chemistry Officer | Purchase (P): 100,000 @ $0.69 | EDGAR |
| 2025-03-27 | 4 | Vaddi Krishna — CEO, Director | Purchase (P): 675,000 @ $0.69 | EDGAR |
| 2025-03-24 | 4 | Vaddi Krishna — CEO, Director | Purchase (P): 5,416 @ $0.73 · Purchase (P): 15,000 @ $0.73 | EDGAR |
| 2025-03-18 | 4 | Vaddi Krishna — CEO, Director | Purchase (P): 29,999 @ $0.75 · Purchase (P): 9,106 @ $0.75 | EDGAR |
| 2025-03-14 | 4 | Vaddi Krishna — CEO, Director | Purchase (P): 47,500 @ $0.71 · Purchase (P): 50,000 @ $0.72 | EDGAR |
| 2025-02-05 | 4 | Lim Bryant David — CLO, CFO, Corp Sec. | Grant/award (A): 200,000 (derivative) @ $0 | EDGAR |
| 2025-02-05 | 4 | Scherle Peggy — Chief Scientific Officer | Grant/award (A): 175,000 (derivative) @ $0 | EDGAR |
| 2025-02-05 | 4 | Combs Andrew — Chief Chemistry Officer | Grant/award (A): 175,000 (derivative) @ $0 | EDGAR |
| 2025-02-05 | 4 | Huang Jane — President, CMO | Grant/award (A): 200,000 (derivative) @ $0 | EDGAR |
| 2025-02-05 | 4 | Vaddi Krishna — CEO, Director | Grant/award (A): 496,000 (derivative) @ $0 | EDGAR |
Recent 8-K events — Prelude Therapeutics Inc
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-08-11 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-10 | 8-K | 5.07 — Submission of Matters to a Vote of Security Holders | EDGAR |
| 2026-05-12 | 8-K | 2.02 — Results of Operations and Financial Condition 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-04-21 | 8-K | 1.01 — Entry into a Material Definitive Agreement 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-04-20 | 8-K | 7.01 — Regulation FD Disclosure 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-04-15 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-03-12 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-03-10 | 8-K | 2.02 — Results of Operations and Financial Condition 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-02-03 | 8-K | 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-01-09 | 8-K | 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=PRLD returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →